Core Viewpoint - The company expresses confidence in the development of the brain-computer interface (BCI) industry due to supportive policies from the government and clear medical insurance charging mechanisms [1] Group 1: Company Development - The company plans to continue investing in core technology research and development for brain-computer interfaces [1] - The company aims to advance the application of BCI technology in both serious medical and consumer scenarios [1] - The company is actively responding to the national strategy for independent innovation [1] Group 2: Industry Context - The encouragement and support from national and local governments for the BCI industry are expected to drive further development [1] - The clarification of medical insurance charging mechanisms is seen as a catalyst for the growth of the BCI sector [1]

Group 1 - The core point of the article highlights the recent performance of Chengyitong (300430), which closed at 19.93 yuan, down 1.39% as of August 1, 2025, with a trading volume of 12.18 million shares and a transaction amount of 2.45 billion yuan [1] - The company experienced a net outflow of main funds amounting to 18.98 million yuan, accounting for 7.74% of the transaction amount, with significant outflows from large orders and super large orders [1] - Chengyitong's latest quarterly report shows total operating revenue of 189 million yuan, a year-on-year decrease of 29.42%, and a net profit attributable to shareholders of 12.59 million yuan, down 59.09% year-on-year [1] Group 2 - Chengyitong has made investments in 9 companies and participated in 107 bidding projects, indicating active engagement in business development [2] - The company holds 44 trademark registrations and 157 patents, showcasing its focus on intellectual property [2] - Chengyitong has 9 administrative licenses, reflecting its compliance and operational capabilities [2]

北京诚益通控制技术集团股份有限公司 证券代码：300430 证券简称：诚益通 公告编号：2025-033 关于使用闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京诚益通控制技术集团股份有限公司（以下简称"公司"）于 2025 年 5 月 14 日召开 2024 年度股东大会，审议通过了《关于使用闲置自有资金进行委托 理财的议案》。同意公司及子公司使用额度不超过 1 亿元人民币的闲置自有资金 进行委托理财，购买低风险、流动性好、安全性高的理财产品，上述额度可由公 司及子公司共同滚动使用，并授权公司管理层具体实施相关事宜，期限自 2024 年度股东大会审议通过之日起至 2025 年度股东大会召开之日止，同意对相关理 财的资金情况每月定期披露进展。 近日公司及子公司使用闲置自有资金在授权范围内购买了理财产品，现将相 关事项公告如下： | 投资主体 | 受托方 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年化收 益率 | | --- | --- | --- | --- | --- | --- ...

天眼查商业履历信息显示，北京诚益通控制技术集团股份有限公司，成立于2003年，位于北京市，是一 家以从事科技推广和应用服务业为主的企业。企业注册资本27304.7596万人民币，实缴资本9979.1427万 人民币。公司法定代表人为梁凯。 通过天眼查大数据分析，北京诚益通控制技术集团股份有限公司共对外投资了9家企业，参与招投标项 目107次，知识产权方面有商标信息44条，专利信息157条，此外企业还拥有行政许可9个。 来源：金融界 金融界消息 截至2025年7月30日收盘，诚益通（300430）报收于20.12元，下跌2.61%，换手率6.62%， 成交量17.21万手，成交金额3.51亿元。 资金流向方面，今日主力资金净流出2732.76万元，占比成交额7.79%。其中，超大单净流出2565.21万 元、占成交额7.31%，大单净流出167.55万元、占成交额0.48%，中单净流出流入1555.98万元、占成交 额4.43%，小单净流入1176.78万元、占成交额3.35%。 诚益通最新一期业绩显示，截至2025一季报，公司营业总收入1.89亿元、同比减少29.42%，归属净利润 1259.18万元，同比减 ...

Group 1 - The Beijing Future Science City Management Committee has developed a draft implementation plan for the "Artificial Intelligence + Pharmaceutical Health" industry in Changping District, focusing on brain-computer interface (BCI) innovation [1] - The plan emphasizes the development and application of BCI products, supporting research in key areas such as neural signal acquisition, decoding, control, and feedback [1] - The document encourages medical and health institutions in the region to adopt BCI products for clinical applications in treating neurological and mental disorders, as well as in smart rehabilitation and health monitoring [1] Group 2 - Open Source Securities highlights the significant potential of the downstream application market for brain-computer interfaces, which connect the brain with external devices for information exchange [2] - The BCI technology is expected to accelerate its implementation due to favorable policies and technological advancements, benefiting companies such as Rock Mountain Technology, Zhongke Information, and others [2] - The applications of BCI span across medical fields for disease warning, diagnosis, treatment, and functional enhancement, as well as in consumer and industrial sectors [2]

Group 1 - The core viewpoint of the article highlights the commencement of construction for two key centers by Chengyitong, marking a new phase in the brain-computer interface (BCI) sector [1] - The BCI technology research validation center will focus on cutting-edge theories, key technologies, new materials, and core devices, aiming to create a complete innovation chain from basic research to engineering application [1] - The animal experiment center will provide in vivo research and application validation for core BCI technologies, equipped with facilities for various experimental capabilities, supporting the transition of BCI from laboratory to clinical applications [1] Group 2 - The construction ceremony took place on July 8, 2025, at the Beijing Daxing Biomedical Industry Base, attended by key company executives [1] - The research validation center will conduct studies on neural signal acquisition, processing, and decoding, as well as explore biocompatible materials and closed-loop control algorithms [1] - The animal experiment center will support experiments related to neural coding mechanisms, implantable electrode evaluation, and system integration, facilitating the practical application of BCI technologies [1]

Group 1 - The human brain engineering sector experienced a slight increase of 0.41% on July 11, with a total capital outflow of 583.41 million [1] - A total of 21 stocks in the sector rose, while 8 stocks declined [1] - The top-performing stocks included Meihao Medical (+3.83%), Hanwei Technology (+2.72%), and Zhongke Information (+2.27%) [1] Group 2 - The stocks with the largest declines were ST Huatuo (-3.87%), Pulite (-1.94%), and Aipeng Medical (-1.72%) [1] - The overall market sentiment showed a mixed performance with significant capital movements in both rising and falling stocks [1]

Investment Rating - The investment rating for the computer industry is optimistic (maintained) [1] Core Insights - The brain-computer interface (BCI) market has significant potential, with global medical applications expected to reach $40 billion by 2030 and $145 billion by 2040 [5][36] - The technology is maturing, with companies like Neuralink receiving FDA approval for human trials, indicating a shift from concept to practical application [6][8] - Policy support is increasing, with various regions in China implementing plans to accelerate the commercialization of BCI technologies [7][45] Summary by Sections 1. Brain-Computer Interface: Continuous Breakthrough - BCI creates a communication channel between the brain and external devices, enabling direct information exchange [17] - The global BCI market was valued at $2.35 billion in 2023, with a projected CAGR of 16.55% from 2023 to 2033 [35] 2. Policy and Technology Resonance: Bright Commercial Prospects for BCI 2.1 Policy: BCI Medical Pricing Implementation Accelerates Commercialization - Major countries are investing in BCI research, with the U.S. and EU leading in funding and project initiatives [41][44] - China's government has issued multiple directives to guide BCI development, including the establishment of independent pricing for BCI services [45][46] 2.2 Technology: Positive Progress in Clinical Trials, Approaching Industrialization - The BCI system faces numerous technical barriers, particularly in balancing performance and commercial viability [48] - China's BCI sector is rapidly advancing, with increasing publications and patents in the field [51][52] 3. Beneficiary Companies 3.1 Neuralink: Pioneer in Invasive BCI Technology - Neuralink is leading in invasive BCI technology, having initiated human trials and planning further patient implants [55][66] 3.2 Strong Brain Technology: Leader in Non-Invasive BCI - Strong Brain Technology focuses on non-invasive BCI solutions, having developed multiple products and secured significant funding [67][69] 3.3 Rock Mountain Technology: Forward-Looking Layout of Brainwave Large Models - Rock Mountain Technology is developing brainwave large models to enhance human-computer interaction systems [80]

Group 1 - The core viewpoint of the news is that Chengyitong Group has initiated the construction of a brain-computer interface (BCI) technology research validation center and an animal experimentation center, marking a new phase in the BCI field [1] - The two centers aim to establish a complete innovation chain from basic research to technology validation and result transformation, reinforcing the company's strategic layout in the BCI sector [1][6] Group 2 - The BCI technology research validation center will focus on cutting-edge theories, key technologies, new materials, and core devices in the BCI field, facilitating the exploration of basic mechanisms to engineering applications [3] - Key research areas include neural signal acquisition, processing and decoding, implantable/wearable electrode materials, biocompatible packaging, neural modulation mechanisms, and closed-loop control algorithms [3] - The center aims to integrate disciplines such as neuroscience, electronic information, artificial intelligence, and materials science to become a core technology source for BCI [3] Group 3 - The BCI animal experimentation center will provide in vivo research and application validation for core BCI technologies, capable of conducting experiments on both small rodents and large mammals [4] - Equipped with standardized surgical rooms, electrophysiological recording and stimulation systems, and behavioral experiment platforms, the center supports multi-channel neural signal acquisition, electrode implantation, long-term recording, closed-loop control, and neural modulation experiments [4] - The center will focus on researching neural coding mechanisms, evaluating implantable electrodes, verifying biocompatibility, and coordinating BCI systems for clinical applications [4] Group 4 - Chengyitong Group adheres to the mission of "making manufacturing smarter and making the public healthier," and the construction of the two centers will further enhance its technological innovation capabilities in the BCI field [6] - The company plans to continue investing in research and development to promote the industrial application of BCI technology, injecting new momentum into the development of the healthcare sector [6]

Group 1 - The brain-computer interface concept sector rose by 0.74%, ranking 8th among concept sectors, with 17 stocks increasing in value [1] - Leading gainers in the sector included Jihua Group, Entropy Technology, and Beiyikang, which rose by 7.59%, 5.92%, and 4.33% respectively [1] - The sector experienced a net inflow of 366 million yuan, with 18 stocks receiving net inflows, and 12 stocks seeing inflows exceeding 10 million yuan [1][2] Group 2 - Jihua Group had the highest net inflow of 331 million yuan, followed by Innovative Medical, Chengyitong, and Zhongke Information with net inflows of 162 million yuan, 77.97 million yuan, and 36.04 million yuan respectively [1][2] - The net inflow ratios for Jihua Group, Chengyitong, and Zhongke Information were 13.23%, 10.52%, and 8.87% respectively [2] - The trading volume and turnover rates for leading stocks in the sector were significant, with Jihua Group showing a turnover rate of 13.84% [2][3]